TCR V GENE REPERTOIRE IN MS AND SELECTIVE IMMUNOTHERAPY
MS 和选择性免疫治疗中的 TCR V 基因库
基本信息
- 批准号:2416309
- 负责人:
- 金额:$ 24.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1992
- 资助国家:美国
- 起止时间:1992-12-01 至 1999-04-30
- 项目状态:已结题
- 来源:
- 关键词:B lymphocyte T cell receptor bacterial antigens gene expression gene mutation gene rearrangement human genetic material tag human tissue immunoglobulin genes immunotherapy laboratory rat multiple sclerosis myelin basic proteins polymerase chain reaction postmortem receptor binding site directed mutagenesis tissue /cell culture transfection
项目摘要
We have discovered VDJ beta and VJ alpha gene rearrangements in MS brain
plaques that encode amino acid sequences identical to those seen in T
cell clones from humans, mice and rats that have specificity for myelin
basic protein (MBP) peptide 87-99. Using a high-efficiency expression
system for TCR alpha and beta chains, we will rigorously prove that a
major T cell response in the MS lesion is directed to MBPp87-99. We have
developed potent T cell receptor antagonists for p87-99 that suppress
ongoing paralysis in rodent models of EAE, and suppress proliferative and
cytotoxic responses to p87-99 in humans. We will determine the putative
contacts for amino acids in the TCR CDR3 regions with residues of p87-99.
A core motif containing MBP87-91 (VHFFK) is found in this epitope. A
number of microbes share sequence homology with this core motif-VHFFK,
and stimulate MBPp87-99 specific T cells. We will determine whether
microbial epitopes can trigger the transfected construct, as efficiently
as the native MBP epitope. This would indicate how these T cells might
become activated during infection, supporting the notion that self-
reactivity arises from the molecular mimicry of self-antigens by
microbes. Since T cells reactive to MBP p87-99 trigger EAE, we will test
whether these microbial sequences either trigger EAE, or alternatively
whether they serve as TCR or MHC antagonists and can block disease
induction. Thus we will consider whether molecular mimics of MBP epitopes
can induce disease or protect from pathology.
We have demonstrated that a dominant antibody response found in the MS
brain plaque and in MS cerebrospinal fluid is directed to an overlapping
region of the MBP molecule from p86-99. This epitope is identical to the
epitope restricted by HLA DR2 beta (HLA DRB1*1501), and overlaps with the
epitope restricted by HLA DR2 alpha (HLA DRB5*0101). We will analyze
immunoglobulin gene rearrangements in MS brain using RT-PCR, and in CSF
using single cell PCR. We will see whether there are restricted Ig CDR3
motifs in MS. We will compare these CDR3 motifs to those found in murine
monoclonal antibodies raised against the identical epitope p86-99. Our
persistent goal is to develop selective immunotherapy for multiple
sclerosis, a chronic disease of the central nervous system affecting
approximately 250,000 Americans.
我们在MS脑中发现了VDJ β和VJ α基因重排
噬斑编码的氨基酸序列与T
来自人类、小鼠和大鼠的对髓磷脂具有特异性的细胞克隆
碱性蛋白(MBP)肽87-99。使用高效表达式
系统的TCR α和β链,我们将严格证明,
MS损伤中的主要T细胞应答针对MBP β 87 -99。我们有
开发了针对p87-99的有效T细胞受体拮抗剂,
在EAE的啮齿动物模型中进行性瘫痪,并抑制增殖和
对人类p87-99的细胞毒性反应。我们将确定
TCR CDR 3区中的氨基酸与p87-99残基的接触。
在该表位中发现含有MBP 87 -91(VHFFK)的核心基序。一
许多微生物与该核心基序-VHFFK共享序列同源性,
并刺激MBP p87 -99特异性T细胞。我们将决定
微生物表位可以有效地触发转染的构建体
作为天然MBP表位。这将表明这些T细胞如何
在感染过程中被激活,支持自我-
反应性来自自身抗原的分子模拟,
微生物由于T细胞对MBP p87-99的反应性触发EAE,我们将测试
这些微生物序列是否触发EAE,或者
无论它们是作为TCR还是MHC拮抗剂,
诱导因此,我们将考虑MBP表位的分子模拟物是否
可以诱发疾病或防止病理。
我们已经证明,在MS中发现的显性抗体应答
脑斑块和MS脑脊液中的斑块是针对重叠的
MBP分子的p86-99区域。该表位与表位相同。
受HLA DR 2 β(HLA DRB 1 *1501)限制的表位,并与
受HLA DR 2 α(HLA DRB 5 *0101)限制的表位。我们将分析
使用RT-PCR在MS脑中和在CSF中的免疫球蛋白基因重排
使用单细胞PCR。我们将观察是否存在受限制的IG CDR 3
我们将比较这些CDR 3基序与在MS中发现的那些。
针对相同表位p86-99产生的单克隆抗体。我们
持续的目标是开发选择性免疫疗法,
硬化症,一种慢性中枢神经系统疾病,
大约25万美国人。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LAWRENCE STEINMAN其他文献
LAWRENCE STEINMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LAWRENCE STEINMAN', 18)}}的其他基金
Autoantibody Arrays Guide Tolergenic Therapy for Multiple Sclerosis
自身抗体阵列指导多发性硬化症的耐受性治疗
- 批准号:
7373008 - 财政年份:2008
- 资助金额:
$ 24.02万 - 项目类别:
Autoantibody Arrays Guide Tolergenic Therapy for Multiple Sclerosis
自身抗体阵列指导多发性硬化症的耐受性治疗
- 批准号:
7777368 - 财政年份:2008
- 资助金额:
$ 24.02万 - 项目类别:
Autoantibody Arrays Guide Tolergenic Therapy for Multiple Sclerosis
自身抗体阵列指导多发性硬化症的耐受性治疗
- 批准号:
8040937 - 财政年份:2008
- 资助金额:
$ 24.02万 - 项目类别:
Autoantibody Arrays Guide Tolergenic Therapy for Multiple Sclerosis
自身抗体阵列指导多发性硬化症的耐受性治疗
- 批准号:
8230528 - 财政年份:2008
- 资助金额:
$ 24.02万 - 项目类别:
Autoantibody Arrays Guide Tolergenic Therapy for Multiple Sclerosis
自身抗体阵列指导多发性硬化症的耐受性治疗
- 批准号:
7586645 - 财政年份:2008
- 资助金额:
$ 24.02万 - 项目类别:
DNA Vaccination for Autoimmunity Immunoinhibitory GpG Mo
自身免疫免疫抑制性 GpG Mo 的 DNA 疫苗接种
- 批准号:
6746106 - 财政年份:2003
- 资助金额:
$ 24.02万 - 项目类别:
Large Scale Images of Gene Transcription in MS and EAE
MS 和 EAE 中基因转录的大规模图像
- 批准号:
6696306 - 财政年份:2001
- 资助金额:
$ 24.02万 - 项目类别:
Large Scale Images of Gene Transcription in MS and EAE
MS 和 EAE 中基因转录的大规模图像
- 批准号:
6435439 - 财政年份:2001
- 资助金额:
$ 24.02万 - 项目类别:
Large Scale Images of Gene Transcription in MS and EAE
MS 和 EAE 中基因转录的大规模图像
- 批准号:
6621627 - 财政年份:2001
- 资助金额:
$ 24.02万 - 项目类别:
相似海外基金
The molecular basis of T cell receptor cross-reactivity between MHC and MR1
MHC 和 MR1 之间 T 细胞受体交叉反应的分子基础
- 批准号:
DP240102905 - 财政年份:2024
- 资助金额:
$ 24.02万 - 项目类别:
Discovery Projects
Machine Learning of Disease Biomarkers from B and T cell Receptor Repertoires
来自 B 和 T 细胞受体库的疾病生物标志物的机器学习
- 批准号:
23K28188 - 财政年份:2024
- 资助金额:
$ 24.02万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
CAREER: Understanding the Impact of Dephosphorylation Kinetics and Adapter Specificity on Synthetic T Cell Receptor Signaling and Function
职业:了解去磷酸化动力学和接头特异性对合成 T 细胞受体信号传导和功能的影响
- 批准号:
2339172 - 财政年份:2024
- 资助金额:
$ 24.02万 - 项目类别:
Continuing Grant
Special Public T Cell Receptor Sequences that Predict Outcomes for Cancer Patients
预测癌症患者预后的特殊公共 T 细胞受体序列
- 批准号:
10577518 - 财政年份:2023
- 资助金额:
$ 24.02万 - 项目类别:
Machine Learning of Disease Biomarkers from B and T cell Receptor Repertoires
来自 B 和 T 细胞受体库的疾病生物标志物的机器学习
- 批准号:
23H03498 - 财政年份:2023
- 资助金额:
$ 24.02万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Impact of T cell receptor signaling on memory CD8+ T cell stemness
T 细胞受体信号传导对记忆 CD8 T 细胞干性的影响
- 批准号:
10676407 - 财政年份:2023
- 资助金额:
$ 24.02万 - 项目类别:
T cell receptor cross-reactivity and structural basis of virus immune escape
T细胞受体交叉反应性和病毒免疫逃逸的结构基础
- 批准号:
22KK0277 - 财政年份:2023
- 资助金额:
$ 24.02万 - 项目类别:
Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
T-cell receptor mimic affinity reagent generation using an in vivo novel immunogen strategy
使用体内新型免疫原策略生成 T 细胞受体模拟亲和试剂
- 批准号:
10599584 - 财政年份:2023
- 资助金额:
$ 24.02万 - 项目类别:
Mechanical regulation of T cell receptor and co-receptor responses in cancer immunotherapy
癌症免疫治疗中 T 细胞受体和辅助受体反应的机械调节
- 批准号:
10530023 - 财政年份:2022
- 资助金额:
$ 24.02万 - 项目类别:
Inhibition of T-cell Receptor Signaling for Treatment of Adult T-cell Leukemia Lymphoma
抑制 T 细胞受体信号转导治疗成人 T 细胞白血病淋巴瘤
- 批准号:
10684172 - 财政年份:2022
- 资助金额:
$ 24.02万 - 项目类别: